Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock - Neurocrine Biosciences ( NASDAQ:NBIX )

3 weeks ago

Wednesday, Neurocrine Biosciences, Inc. ( NASDAQ: NBIX ) topline data for its Phase 2 clinical study of NBI-1117568 ( NBI-'568 ) in adults with schizophrenia.

Ticker	Sentiment	Impact
NBIX	Neutral	38 %